Kissei Pharmaceutical's (TYO:4547) licensing partner, JW Pharmaceutical, launched TAVALISSE (fostamatinib) in South Korea for adult patients with chronic idiopathic thrombocytopenic purpura (ITP) who did not respond to prior treatments, according to a Tokyo bourse filing on Tuesday.
TAVALISSE, an oral spleen tyrosine kinase inhibitor, was originally developed by US-based Rigel Pharmaceuticals and reduces the destruction of platelets in ITP patients.
The drug has already been launched in the US, Europe, Canada, the Middle East, and Japan, and holds orphan drug status in several markets, including South Korea.
Kissei licensed South Korea rights to JW in 2021. The South Korean approval, granted in January 2025, followed Kissei's launch in Japan in April 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.